At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Blinatumomabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Open-label Study to Investigate Safety, Tolerability and Pharmacokinetics of Intravenous Blinatumomab in Japanese Adult Subjects With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
In Brief
A Phase 1 clinical trial evaluating Blinatumomab for B-precursor Acute Lymphoblastic Leukemia. Completed, enrolled 6 participants across 6 sites.
Detailed Summary
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-precursor Acute Lymphoblastic Leukemia
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedOct 2024
Enrollment StartJan 2025
Primary CompletionJul 2025
Study CompletionDec 2025
TodayJul 2026
First PostedOct 18, 2024
Enrollment StartJan 8, 2025
Primary CompletionJul 30, 2025
Study CompletionDec 4, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 1.7 years ago
Interventions
Blinatumomabdrug
IV infusion